Finnhub•2026-04-21
NHC to Acquire Thirty-Five NHI FacilitiesNHC — National Healthcare Corp
AMEX · Health Care · Health Care
$172.86+23.07%Market cap2.51B
- Latest Close
- $172.86
- 30-Day Move
- +23.1%
- Market Cap
- $2.5B
- Shares Outstanding
- 15,540,000
- P/E Ratio
- 20.89
- P/B Ratio
- 1.99
AMEX:NHCHealth Care / Health CareDelayed public snapshot
National Healthcare Corp
A read-only Alphactor snapshot forNational Healthcare Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$172.86
30-Day Move
+23.1%
Market Cap
$2.5B
Shares Outstanding
15,540,000
P/E Ratio
20.89
P/B Ratio
1.99
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$172.86
+23.1%last 90 delayed daily bars
Market cap$2.5B
90D High
$184.08
90D Low
$128.00
Avg Volume
101,039
What stands out
Gross margin is running at 39.3%, which gives a quick read on operating quality before you open the full model.
Net margin is 7.9%, useful for comparing NHC against peers in Health Care.
NHC is up 23.1% over the last 30 trading days shown on this page.
Latest operating income is $128M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$250.74
Rule of 40
26.7%
Dark Pool Short %
62.8%
Fundamentals snapshot
Latest Close
$172.86
30-Day Move
+23.1%
Market Cap
$2.5B
Shares Outstanding
15,540,000
P/E Ratio
20.89
P/B Ratio
1.99
ROE
11.2%
ROA
7.9%
Gross Margin
39.3%
Operating Margin
8.5%
Net Margin
7.9%
Debt / Equity
0.04
Current Ratio
1.82
Dividend Yield
1.6%
Latest Revenue
$1.5B
Financial statement snapshot
Revenue
$1.5B
Gross Profit
$597M
Operating Income
$128M
Net Income
$120M
Gross Margin
3931.0%
Net Margin
791.0%
Current Ratio
1.82
Debt / Equity
0.04
Valuation snapshot
Fair Value
$250.74
Upside / Downside
+45.1%
Signal
Undervalued
Implied Growth
4.0%
DCF
$213.64
EPV
$49.86
EV/Rev
$488.72
Growth Assumption
12.2%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$149M
Valuation spread
Current Price
$172.86
Composite Fair Value
$250.74
DCF
$213.64
EPV
$49.86
EV/Rev
$488.72
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Low growth priced in
Quality snapshot
Altman Z
5.53
Safe
Piotroski
9
Strong (7-9)
Cash Conversion
1.54x
Rule of 40
26.7%
Acceptable
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $1.1B | $29M | $22M | $-21M |
| 2023-12-31 | $1.1B | $57M | $67M | $83M |
| 2024-12-31 | $1.3B | $90M | $102M | $80M |
| 2025-12-31 | $1.5B | $128M | $120M | $149M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$2M
Buys
0
Sells
4
Buy Value
$0
Sell Value
$2M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-22 | Dodson Vicki L | M | 4,000 | $0.00 |
| 2026-04-22 | Dodson Vicki L | F | 2,853 | $173.63 |
| 2026-04-22 | Dodson Vicki L | M | 4,000 | $94.10 |
| 2026-04-09 | FLATT BEN ANDERSON SR | F | 2,109 | $176.81 |
| 2026-04-09 | FLATT BEN ANDERSON SR | M | 3,734 | $0.00 |
| 2026-04-09 | FLATT BEN ANDERSON SR | F | 1,909 | $176.81 |
| 2026-04-09 | FLATT BEN ANDERSON SR | M | 3,734 | $53.94 |
| 2026-03-16 | Dodson Vicki L | M | 3,734 | $0.00 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 753,838 | 0.05% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 391,387 | 0.03% | 2025-12-31 |
| First TRT Exch-Trd Fd. VI-First TRT SMID Cap Rising Dividend Achievers | 346,968 | 0.02% | 2026-02-28 |
| iShares Trust-iShares Russell 2000 ETF | 307,863 | 0.02% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 281,036 | 0.02% | 2025-12-31 |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Value Portfolio | 203,655 | 0.01% | 2026-01-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 181,612 | 0.01% | 2025-12-31 |
| ALPS ETF TRUST-ALPS O'Shares U.S. Small-Cap Quality Dividend ETF | 167,332 | 0.01% | 2025-11-30 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
BlackRock
Filed 2024-08-13
$226M
--
Vanguard Group
Filed 2026-01-29
$194M
-0.7%
Renaissance Technologies
Filed 2026-02-12
$48M
-6.4%
Geode Capital Management
Filed 2026-02-09
$44M
+0.7%
Dark-pool activity snapshot
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.